Back to Search
Start Over
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2000 Nov; Vol. 44 (11), pp. 3155-7. - Publication Year :
- 2000
-
Abstract
- We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.
Details
- Language :
- English
- ISSN :
- 0066-4804
- Volume :
- 44
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 11036040
- Full Text :
- https://doi.org/10.1128/AAC.44.11.3155-3157.2000